EQRx backtracks on plans to reduce pricing of lead cancer treatments
For its two lead oncology programs, the company will pursue “market-based pricing”, moving away from plans to “dramatically lower prices” for treatments.
Archives for November 21, 2022
Mitochondria-focused biotech receives funding for neurodegenerative conditions
NRG Therapeutics receives an injection of capital to advance its oral medicines for Parkinson's disease and ALS.
Arrowhead cashes in to sell royalty rights to heart drug for $250m
Royalty Pharma will acquire the royalty interest for olpasiran, which is being developed by Amgen.